Proxy Blog

Biogen Inc. 

May 5, 2020

The annual proxy for this biotechnology company had the following proposals: 

  • Proforma proposals on directors, appointment of auditors, and “say-on-pay” advisory vote 

Magni voted for and against proforma proposals. 

  • For and against directors – One of the directors, Robert Pangia, is a legacy of an acquisition. The expertise he provided following the acquisition should be complete. Someone else should get this board seat. Magni supported the other nominees. 
  • For auditors – There appear to be no controversies with the financial statements of the company. 
  • Against say-on-pay”  The proxy materials did not disclose a benchmarking of the company to the peer groups.